Acorda Therapeutics, Inc. (ACOR): Price and Financial Metrics

Acorda Therapeutics, Inc. (ACOR): $4.71

0.05 (+1.07%)

POWR Rating

Component Grades













Add ACOR to Watchlist
Sign Up

Industry: Biotech


of 504

in industry


  • Value is the dimension where ACOR ranks best; there it ranks ahead of 86.26% of US stocks.
  • ACOR's strongest trending metric is Momentum; it's been moving down over the last 51 weeks.
  • ACOR ranks lowest in Stability; there it ranks in the 2nd percentile.

ACOR Stock Summary

  • With a market capitalization of $51,838,534, Acorda Therapeutics Inc has a greater market value than merely 7.63% of US stocks.
  • ACOR's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.82 -- higher than merely 4.6% of US-listed equities with positive expected earnings growth.
  • With a price/sales ratio of 0.34, Acorda Therapeutics Inc has a higher such ratio than only 5.51% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Acorda Therapeutics Inc, a group of peers worth examining would be PRGO, OSMT, SYTA, HAS, and NVT.
  • ACOR's SEC filings can be seen here. And to visit Acorda Therapeutics Inc's official web site, go to

ACOR Valuation Summary

  • ACOR's price/earnings ratio is -0.4; this is 101.1% lower than that of the median Healthcare stock.
  • ACOR's price/earnings ratio has moved up 1.7 over the prior 189 months.
  • Over the past 189 months, ACOR's price/earnings ratio has gone up 1.7.

Below are key valuation metrics over time for ACOR.

Stock Date P/S P/B P/E EV/EBIT
ACOR 2021-08-31 0.3 0.2 -0.4 -1.5
ACOR 2021-08-30 0.3 0.2 -0.3 -1.5
ACOR 2021-08-27 0.3 0.2 -0.4 -1.5
ACOR 2021-08-26 0.3 0.2 -0.4 -1.5
ACOR 2021-08-25 0.3 0.2 -0.4 -1.5
ACOR 2021-08-24 0.3 0.2 -0.3 -1.5

ACOR Growth Metrics

  • The 3 year revenue growth rate now stands at -19.52%.
  • Its 5 year revenue growth rate is now at -64.2%.
  • Its 4 year price growth rate is now at -96.98%.
Over the past 15 months, ACOR's revenue has gone down $24,474,000.

The table below shows ACOR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 151.897 -37.033 -132.016
2021-03-31 153.73 -49.115 -126.573
2020-12-31 152.967 -61.006 -99.594
2020-09-30 165.304 -73.883 49.114
2020-06-30 159.936 -95.329 -221.768
2020-03-31 176.371 -89.45 -231.833

ACOR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ACOR has a Quality Grade of C, ranking ahead of 72.83% of graded US stocks.
  • Service Unavailable
  • BDSI, INVA, and CALA are the stocks whose asset turnover ratios are most correlated with ACOR.

The table below shows ACOR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.251 0.695 -0.414
2021-03-31 0.232 0.729 -0.327
2020-12-31 0.217 0.781 -0.207
2020-09-30 0.221 0.810 0.173
2020-06-30 0.202 0.830 -0.419
2020-03-31 0.194 0.831 -0.393

ACOR Price Target

For more insight on analysts targets of ACOR, see our ACOR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.00 Average Broker Recommendation 1.5 (Moderate Buy)

ACOR Stock Price Chart Interactive Chart >

Price chart for ACOR

ACOR Price/Volume Stats

Current price $4.71 52-week high $9.84
Prev. close $4.66 52-week low $3.27
Day low $4.62 Volume 111,100
Day high $4.90 Avg. volume 743,130
50-day MA $4.25 Dividend yield N/A
200-day MA $4.84 Market Cap 52.39M

Acorda Therapeutics, Inc. (ACOR) Company Bio

Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The company was founded in 1995 and is based in Ardsley, New York.

ACOR Latest News Stream

Event/Time News Detail
Loading, please wait...

ACOR Latest Social Stream

Loading social stream, please wait...

View Full ACOR Social Stream

Latest ACOR News From Around the Web

Below are the latest news stories about Acorda Therapeutics Inc that investors may wish to consider to help them evaluate ACOR as an investment opportunity.

Acorda Therapeutics To Reduce Headcount; Names Lauren Sabella COO - Quick Facts

(RTTNews) - Acorda Therapeutics, Inc. (ACOR) said it is reducing headcount by 15%. The company estimates it will incur approximately $3.0 million of pre-tax charges for severance and other costs related to the restructuring, through the first quarter of 2022. Beginning in 2022, the company expects to realize annualized cost savings of

Business Insider Markets | September 9, 2021

Acorda Therapeutics Announces Corporate Restructuring, Management Changes

ARDSLEY, N.Y., September 09, 2021--Acorda Therapeutics Announces Corporate Restructuring, Management Changes

Yahoo | September 9, 2021

Acorda Therapeutics (ACOR) Reports Q2 Loss, Tops Revenue Estimates

Acorda (ACOR) delivered earnings and revenue surprises of -9.57% and 6.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 5, 2021

Acorda Therapeutics Reports Second Quarter 2021 Financial Results

ARDSLEY, N.Y., August 05, 2021--Acorda Therapeutics Reports Second Quarter 2021 Financial Results

Yahoo | August 5, 2021

Acorda Second Quarter 2021 Update: Webcast/Conference Call Scheduled for August 5, 2021

ARDSLEY, N.Y., July 30, 2021--Acorda Second Quarter 2021 Update: Webcast/Conference Call Scheduled for August 5, 2021

Yahoo | July 30, 2021

Read More 'ACOR' Stories Here

ACOR Price Returns

1-mo -0.42%
3-mo 30.11%
6-mo 13.49%
1-year 17.37%
3-year -95.86%
5-year -96.10%
YTD 13.75%
2020 -66.17%
2019 -86.91%
2018 -27.37%
2017 14.10%
2016 -56.05%

Continue Researching ACOR

Here are a few links from around the web to help you further your research on Acorda Therapeutics Inc's stock as an investment opportunity:

Acorda Therapeutics Inc (ACOR) Stock Price | Nasdaq
Acorda Therapeutics Inc (ACOR) Stock Quote, History and News - Yahoo Finance
Acorda Therapeutics Inc (ACOR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8753 seconds.